Edwards Lifesciences (EW)Officer sold ~$13K
Wayne Markowitz, Officer at Edwards Lifesciences, sold ~$13K of Edwards Lifesciences shares.
- ~$13K
- Approx. value · 146.31 sh @ $86.03
- 22K
- Holds after · shares reported
- Traded
- Jul 30, 2026
- Filed
- Jul 30, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 27, 2026CongressDisclosed purchase of EW — reported range $1,001 - $15,000
- Jun 5, 2026FDAFDA device clearance: Fogarty Spring Clips, Handleless Clamps, and Clamp Inserts
- Jun 11, 2026FDAFDA device clearance: Respiration Rate algorithm
- Jun 17, 2026InsiderCEO sold ~$46K of EW shares in the open market
- Jun 26, 2026FDAFDA device clearance: ECLIPTIS Left Atrial Appendage Exclusion System (ECS135); ECLIPTIS Left Atrial Appendage Exclusion System (ECS140); ECLIPTIS Left Atrial Appendage Exclusion Sy…
- Jun 30, 2026InsiderOfficer sold ~$57K of EW shares in the open market
- Jul 10, 2026InsiderOfficer sold ~$57K of EW shares in the open market
- Jul 23, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 23, 2026Government · Federal Register noticeUnited States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
- Jul 27, 2026InsiderCEO sold ~$245K of EW shares in the open market
- Jul 28, 2026InsiderOfficer sold ~$819K of EW shares in the open market
- Jul 30, 2026 · this disclosureInsiderOfficer sold ~$13K of EW shares in the open market
What came next
- Aug 11, 2026InsiderOfficer sold ~$57K of EW shares in the open market
- Aug 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.”
- Aug 26, 2026Insider · 2 peopleInsiders: 3 sales (~$3.0M)
- Aug 28, 2026InsiderOfficer sold ~$238K of EW shares in the open market
- Aug 31, 2026InsiderOfficer sold ~$50K of EW shares in the open market
- Sep 11, 2026InsiderOfficer sold ~$54K of EW shares in the open market
- Oct 8, 2026InsiderOfficer sold ~$53K of EW shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Edwards Lifesciences
For Edwards Lifesciences, OQRO holds 11 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 21 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.
Other recent filings by Wayne Markowitz, CVP, JAPAC
- SEC Form 4 at Edwards Lifesciences (EW)Aug 26, 2026
- SEC Form 4 at Edwards Lifesciences (EW)Jul 28, 2026
- SEC Form 4 at Edwards Lifesciences (EW)May 12, 2026
- SEC Form 4 at Edwards Lifesciences (EW)Dec 8, 2025
- SEC Form 4 at Edwards Lifesciences (EW)May 9, 2025
The full history of Wayne Markowitz, CVP, JAPAC is on the profile page.
How this filing works
Other disclosures at Edwards Lifesciences
- SEC Form 4Oct 8, 2026
- SEC Form 4Sep 11, 2026
- SEC Form 4Aug 31, 2026
- SEC Form 4Aug 28, 2026
- SEC Form 4Aug 26, 2026
- SEC Form 4Aug 26, 2026
Everything OQRO holds on this company is on its EW page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
